PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
48.8%−33.9 pts over 5 years
Operating margin
-10.4%−14.7 pts over 5 years
Net margin
-12.5%−2.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.2% | +3.5% | -3.5% | +28.3% | |
| Gross profit | -11.4% | -2.8% | -13.1% | +21.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -6411.6% | 13.4% | -14.4% | |
| Return on assets | -32.7% | -11.5% | -8.5% | |
| Current ratio | 1.09 | 0.64 | 2.51 | |
| Inventory turnover | 1.5× | 1.0× | 1.1× | |
| Capex to revenue | 9.2% | 1.0% | 3.1% | |
| Diluted shares | 10M | 29M | 79M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Protalix BioTherapeutics generated $57.27M from operations and spent $6.16M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$57.27M
Used
$6.16M
Capital expenditure$6.16M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-12.5%
×Asset turnover0.68×
×Equity multiplier1.70×
=Return on equity, FY2025-14.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -12.5% | 0.68× | 1.70× | -14.4% |
| FY2024 | 5.5% | 0.68× | 2.06× | 7.6% |
| FY2023 | 12.7% | 0.93× | 6.12× | 72.5% |
| FY2022 | -31.3% | 0.74× | -7.76× | 179.0% |
| FY2021 | -71.9% | 0.54× | -4.28× | 166.8% |
| FY2020 | -10.4% | 1.11× | -1.16× | 13.4% |
| FY2019 | -33.4% | 1.03× | -0.86× | 29.7% |
| FY2018 | -77.3% | 0.51× | -1.62× | 64.3% |
| FY2017 | -395.9% | 0.27× | -3.92× | 423.4% |
| FY2016 | -319.2% | 0.10× | 195.96× | -6411.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$6.60M
- Cash generatingOperating cash flow above zero-$11.99M
- Return on assets improvedROA up on the prior year3.5% → -9.0%
- Earnings backed by cashOperating cash flow above net income-$11.99M vs -$6.60M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.34 → 2.51
- No dilutionShare count did not rise81M → 79M
- Gross margin improvedGross margin up on the prior year54.46% → 48.82%
- More efficientAsset turnover rose0.63 → 0.72